Drug research for the benefit of medical care;Geneesmiddelenonderzoek in, van en voor de zorg

Pharmaceutisch Weekblad

Volumn 138, Issue 49, 2003, Pages 1742-1745

  Herings, R M C ^a  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DYSLIPIDEMIA; HUMAN; MEDICAL CARE;

EID: 0344552368     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Stricker BHC, Herings RM, Bakker A, et al. Farmacomorbidteitskoppeling; een potentieel instrument voor 'post marketing surveillance'. Ned Tijdschr Geneeskd 1990;134(39):1886-9.
2. Herings RM, De Boer A, Stricker BH, et al. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995; 345(8959):1195-8.
3. Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999;354(9173):127-8.
4. Panneman MJM, et al. An assessment of the economic burden of benzodiazepine-associated accidental falls in the European Union. Drugs Aging 2003, Ter perse.